AZ12216052

AZ12216052
Identifiers
	IUPAC name 2-[(4-bromophenyl)methylsulfanyl]-N-(4-butan-2-ylphenyl)acetamide;
CAS Number	1290628-31-7 ;
PubChem CID	73755190;
ChemSpider	29342334;
Chemical and physical data
Formula	C19H22BrNOS
Molar mass	392.36 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(C)C1=CC=C(C=C1)NC(=O)CSCC2=CC=C(C=C2)Br;
	InChI InChI=1S/C19H22BrNOS/c1-3-14(2)16-6-10-18(11-7-16)21-19(22)13-23-12-15-4-8-17(20)9-5-15/h4-11,14H,3,12-13H2,1-2H3,(H,21,22); Key:QKUYZJOTWYRWNF-UHFFFAOYSA-N;

AZ-12216052 is a drug which acts as a potent and selective positive allosteric modulator of the metabotropic glutamate receptor 8, and is used for research into the role of this receptor subtype in various processes including anxiety and neuropathic pain.^[1]^[2]^[3]^[4]^[5]

References[edit]

^ Duvoisin RM, Pfankuch T, Wilson JM, Grabell J, Chhajlani V, Brown DG, et al. (October 2010). "Acute pharmacological modulation of mGluR8 reduces measures of anxiety". Behavioural Brain Research. 212 (2): 168–173. doi:10.1016/j.bbr.2010.04.006. PMC 2892883. PMID 20385173.
^ Reed BT, Morgans CW, Duvoisin RM (April 2013). "Differential modulation of retinal ganglion cell light responses by orthosteric and allosteric metabotropic glutamate receptor 8 compounds". Neuropharmacology. 67: 88–94. doi:10.1016/j.neuropharm.2012.09.023. PMC 3562428. PMID 23164615.
^ Rossi F, Marabese I, De Chiaro M, Boccella S, Luongo L, Guida F, et al. (June 2014). "Dorsal striatum metabotropic glutamate receptor 8 affects nocifensive responses and rostral ventromedial medulla cell activity in neuropathic pain conditions". Journal of Neurophysiology. 111 (11): 2196–2209. doi:10.1152/jn.00212.2013. PMID 24304862.
^ Jantas D, Greda A, Leskiewicz M, Grygier B, Pilc A, Lason W (September 2015). "Neuroprotective effects of mGluR II and III activators against staurosporine- and doxorubicin-induced cellular injury in SH-SY5Y cells: New evidence for a mechanism involving inhibition of AIF translocation". Neurochemistry International. 88: 124–137. doi:10.1016/j.neuint.2014.12.011. PMID 25661514. S2CID 8865211.
^ Jantas D, Grygier B, Zatorska J, Lasoń W (October 2018). "Allosteric and Orthosteric Activators of mGluR8 Differentially Affect the Chemotherapeutic-Induced Human Neuroblastoma SH-SY5Y Cell Damage: The Impact of Cell Differentiation State". Basic & Clinical Pharmacology & Toxicology. 123 (4): 443–451. doi:10.1111/bcpt.13041. PMID 29753314. S2CID 21666589.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Duvoisin RM, Pfankuch T, Wilson JM, Grabell J, Chhajlani V, Brown DG, et al. (October 2010). "Acute pharmacological modulation of mGluR8 reduces measures of anxiety". Behavioural Brain Research. 212 (2): 168–173. doi:10.1016/j.bbr.2010.04.006. PMC 2892883. PMID 20385173.

[2] Reed BT, Morgans CW, Duvoisin RM (April 2013). "Differential modulation of retinal ganglion cell light responses by orthosteric and allosteric metabotropic glutamate receptor 8 compounds". Neuropharmacology. 67: 88–94. doi:10.1016/j.neuropharm.2012.09.023. PMC 3562428. PMID 23164615.

[3] Rossi F, Marabese I, De Chiaro M, Boccella S, Luongo L, Guida F, et al. (June 2014). "Dorsal striatum metabotropic glutamate receptor 8 affects nocifensive responses and rostral ventromedial medulla cell activity in neuropathic pain conditions". Journal of Neurophysiology. 111 (11): 2196–2209. doi:10.1152/jn.00212.2013. PMID 24304862.

[4] Jantas D, Greda A, Leskiewicz M, Grygier B, Pilc A, Lason W (September 2015). "Neuroprotective effects of mGluR II and III activators against staurosporine- and doxorubicin-induced cellular injury in SH-SY5Y cells: New evidence for a mechanism involving inhibition of AIF translocation". Neurochemistry International. 88: 124–137. doi:10.1016/j.neuint.2014.12.011. PMID 25661514. S2CID 8865211.

[5] Jantas D, Grygier B, Zatorska J, Lasoń W (October 2018). "Allosteric and Orthosteric Activators of mGluR8 Differentially Affect the Chemotherapeutic-Induced Human Neuroblastoma SH-SY5Y Cell Damage: The Impact of Cell Differentiation State". Basic & Clinical Pharmacology & Toxicology. 123 (4): 443–451. doi:10.1111/bcpt.13041. PMID 29753314. S2CID 21666589.

[1]

[2]

[3]

[4]

[5]